scholarly journals Pharmacological and clinical profile of linaclotide (Linzess®), a novel therapeutic agent for irritable bowel syndrome with constipation and chronic constipation

2019 ◽  
Vol 153 (6) ◽  
pp. 289-298
Author(s):  
Yoshihiro Keto ◽  
Masanori Kosako
Keyword(s):  
Irritable Bowel Syndrome ◽  
Chronic Constipation ◽  
Therapeutic Agent ◽  
Clinical Profile ◽  
Irritable Bowel ◽  
Novel Therapeutic

scholarly journals Pharmacological and clinical profile of ramosetron hydrochloride (Irribow®), a novel therapeutic agent for irritable bowel syndrome with diarrhea

2009 ◽  
Vol 133 (5) ◽  
pp. 281-291
Author(s):  
Takuya Hirata ◽  
Toshiyuki Funatsu ◽  
Yoshihiro Keto ◽  
Shinobu Akuzawa ◽  
Hiraku Akiho ◽  
...  
Keyword(s):  
Irritable Bowel Syndrome ◽  
Therapeutic Agent ◽  
Clinical Profile ◽  
Irritable Bowel ◽  
Novel Therapeutic

scholarly journals Evaluation of the Pharmacological Profile of Ramosetron, a Novel Therapeutic Agent for Irritable Bowel Syndrome

2007 ◽  
Vol 104 (3) ◽  
pp. 263-273 ◽  
Author(s):  
Takuya Hirata ◽  
Yoshihiro Keto ◽  
Toshiyuki Funatsu ◽  
Shinobu Akuzawa ◽  
Masao Sasamata
Keyword(s):  
Irritable Bowel Syndrome ◽  
Therapeutic Agent ◽  
Pharmacological Profile ◽  
Irritable Bowel ◽  
Novel Therapeutic

scholarly journals EFFICACY AND SAFETY OF INTESTINAL SECRETAGOGUES FOR CHRONIC CONSTIPATION: A SYSTEMATIC REVIEW AND META-ANALYSIS

2018 ◽  
Vol 55 (suppl 1) ◽  
pp. 2-12 ◽  
Author(s):  
Juan Sebastian LASA ◽  
María Josefina ALTAMIRANO ◽  
Luis Florez BRACHO ◽  
Silvina PAZ ◽  
Ignacio ZUBIAURRE
Keyword(s):  
Irritable Bowel Syndrome ◽  
Chronic Constipation ◽  
Meta Analysis ◽  
Efficacy And Safety ◽  
Spontaneous Bowel Movement ◽  
Intention To Treat ◽  
Mesh Terms ◽  
Bowel Movements ◽  
Irritable Bowel ◽  
Therapeutic Alternatives

ABSTRACT BACKGROUND: Intestinal secretagogues have been tested for the treatment of chronic constipation and constipation-predominant irritable bowel syndrome. The class-effect of these type of drugs has not been studied. OBJECTIVE: To determine the efficacy and safety of intestinal secretagogues for the treatment of chronic constipation and constipation-predominant irritable bowel syndrome. METHODS: A computer-based search of papers from 1966 to September 2017 was performed. Search strategy consisted of the following MESH terms: intestinal secretagogues OR linaclotide OR lubiprostone OR plecanatide OR tenapanor OR chloride channel AND chronic constipation OR irritable bowel syndrome. Data were extracted as intention-to-treat analyses. A random-effects model was used to give a more conservative estimate of the effect of individual therapies, allowing for any heterogeneity among studies. Outcome measures were described as Relative Risk of achieving an improvement in the symptom under consideration. RESULTS: Database Search yielded 520 bibliographic citations: 16 trials were included for analysis, which enrolled 7658 patients. Twelve trials assessed the efficacy of intestinal secretagogues for chronic constipation. These were better than placebo at achieving an increase in the number of complete spontaneous bowel movements per week [RR 1.87 (1.24-2.83)], at achieving three or more spontaneous bowel movements per week [RR 1.56 (1.31-1.85)] and at inducing spontaneous bowel movement after medication intake [RR 1.49 (1.07-2.06)]. Similar results were observed when assessing the efficacy of intestinal secretagogues on constipation-predominant irritable bowel syndrome based on the results of six trials. CONCLUSION: Intestinal secretagogues are useful and safe therapeutic alternatives for the treatment of constipation-related syndromes.

scholarly journals Recommendations on Chronic Constipation (Including Constipation Associated with Irritable Bowel Syndrome) Treatment

2007 ◽  
Vol 21 (suppl b) ◽  
pp. 3B-22B ◽  
Author(s):  
Pierre Paré ◽  
Ronald Bridges ◽  
Malcolm C Champion ◽  
Subhas C Ganguli ◽  
James R Gray ◽  
...  
Keyword(s):  
Irritable Bowel Syndrome ◽  
Health Care Professionals ◽  
Chronic Constipation ◽  
Clinical Care ◽  
Treatment Algorithm ◽  
Treatment Recommendations ◽  
Lifestyle Changes ◽  
Bulking Agents ◽  
Consensus Group ◽  
Irritable Bowel

While chronic constipation (CC) has a high prevalence in primary care, there are no existing treatment recommendations to guide health care professionals. To address this, a consensus group of 10 gastroenterologists was formed to develop treatment recommendations. Although constipation may occur as a result of organic disease, the present paper addresses only the management of primary CC or constipation associated with irritable bowel syndrome. The final consensus group was assembled and the recommendations were created following the exact process outlined by the Canadian Association of Gastroenterology for the following areas: epidemiology, quality of life and threshold for treatment; definitions and diagnostic criteria; lifestyle changes; bulking agents and stool softeners; osmotic agents; prokinetics; stimulant laxatives; suppositories; enemas; other drugs; biofeedback and behavioural approaches; surgery; and probiotics. A treatment algorithm was developed by the group for CC and constipation associated with irritable bowel syndrome. Where possible, an evidence-based approach and expert opinions were used to develop the statements in areas with insufficient evidence. The nature of the underlying pathophysiology for constipation is often unclear, and it can be tricky for physicians to decide on an appropriate treatment strategy for the individual patient. The myriad of treatment options available to Canadian physicians can be confusing; thus, the main aim of the recommendations and treatment algorithm is to optimize the approach in clinical care based on available evidence.

Sign in / Sign up

Export Citation Format

Share Document